Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19080985 | 0.90 | ALOX5 (0.34) | ALOX5ABCG2ABCB1ABCC1PRKDC | |
| SCHEMBL19080703 | 0.90 | CYP1A1 (0.40) | ABCG2ABCB1ABCC1PRKDCCYP1A1 | |
| SCHEMBL19091559 | 0.86 | — | — | |
| SCHEMBL19080923 | 0.85 | CYP1A1 (0.37) | ABCG2ABCB1ABCC1PRKDCCYP1A1 | |
| SCHEMBL19081007 | 0.85 | ABCG2 (0.35) | ALOX5ABCG2ABCB1ABCC1PRKDC | |
| SCHEMBL17944864 | 0.85 | HCRTR1 (0.34) | ALOX5PRKDCPGRHCRTR1KMT2A | |
| SCHEMBL17945020 | 0.84 | AHR (0.36) | ALOX5PRKDCPGRHCRTR1KMT2A | |
| SCHEMBL17945354 | 0.84 | ALOX5 (0.34) | ALOX5PRKDCPGR | |
| SCHEMBL19081364 | 0.83 | CYP1A1 (0.31) | PGRHCRTR1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL17945138 | 0.83 | ALOX5 (0.36) | ALOX5PRKDCPGRCYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | ALOX5 1939/4885ABCG2 4823/4885ABCB1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.